Ninlaro

Generic name: Ixazomib
Drug class: Proteasome inhibitors

Usage of Ninlaro

Ninlaro is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

Ninlaro is used in adults to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and Dexamethasone.

This combination is usually given after treatment with at least one other cancer medicine has failed.

Ninlaro should not be used to treat people who are receiving maintenance treatment, or who have been newly diagnosed with multiple myeloma, except if they are participants in a controlled clinical trial.

Ninlaro side effects

Get emergency medical help if you have signs of an allergic reaction to Ninlaro (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, mouth sores, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Ixazomib can cause life-threatening blood clots in the small blood vessels inside your organs, such as your brain or kidneys. Seek medical help right away if you have symptoms of this condition, such as a fever, tiredness, decreased urination, bruising, or nosebleeds.

Call your doctor at once if you have:

severe ongoing nausea, vomiting, diarrhea, or constipation;

a new or worsening skin rash;

blurred vision, dry or red eyes;

back pain;

fluid retention - swelling in your hands or feet, rapid weight gain;

liver problems - upper stomach pain, jaundice (yellowing of the skin or eyes);

low levels of platelets in your blood - easy bruising, unusual bleeding, purple or red spots under your skin;

low white blood cell counts - fever, cold or flu symptoms, cough, sore throat, swollen gums, mouth sores, skin sores;

nerve problems - numbness, tingling, pain, burning feeling in your hands or feet, weakness in your arms or legs; or

signs of shingles - flu-like symptoms, tingly or painful blistering rash on one side of your body.

Common Ninlaro side effects may include:

nerve problems or swelling in your hands or feet;

low blood platelets;

diarrhea, constipation;

nausea, vomiting; or

back pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Ninlaro

You should not use Ninlaro if you are allergic to ixazomib.

To make sure Ninlaro is safe for you, tell your doctor if you have ever had:

liver disease; or

kidney disease (or if you are on dialysis).

Ixazomib may harm an unborn baby. Both men and women should use effective birth control to prevent pregnancy while taking Ninlaro, and for at least 90 days after the last dose.

If you are a woman also taking dexamethasone: If you use birth control pills or other hormonal contraception (injections, implants, skin patches, vaginal rings), also use a barrier form of birth control such as a condom, diaphragm, cervical cap, or contraceptive sponge.

Ninlaro is used together with lenalidomide. Do not use Ninlaro with lenalidomide if you are pregnant, or if you are a man and your sex partner is pregnant. Lenalidomide is known to cause severe, life-threatening birth defects or death of a baby if the mother or the father is taking this medicine at the time of conception or during pregnancy.

Carefully follow all instructions about the use of birth control while using Ninlaro with lenalidomide, whether you are a man or a woman. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using these medicines.

Do not breastfeed while using Ninlaro, and for at least 90 days after your last dose.

Relate drugs

How to use Ninlaro

Usual Adult Dose for Multiple Myeloma:

Starting dose: 4 mg orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle Duration of therapy: Until disease progression or unacceptable toxicity Comments: -Limitations of Use: This drug is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials. -The recommended starting dose of lenalidomide is 25 mg orally daily on Days 1 through 21 of a 28-day treatment cycle; the recommended starting dose of dexamethasone is 40 mg orally on Days 1, 8, 15, and 22 of a 28-day treatment cycle. -The manufacturer product information for lenalidomide and dexamethasone should each be consulted. Use: In combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 1 prior therapy

Warnings

Do not use Ninlaro with lenalidomide if you are pregnant, or if you are a man and your sexual partner is pregnant. Lenalidomide is known to cause severe, life-threatening birth defects or death of a baby if the mother or the father is taking this medicine at the time of conception or during pregnancy.

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Ninlaro

Other drugs may interact with ixazomib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.